How The MDR Is Making The EU Competitively Backward
Executive Summary
Pedantic versus pragmatic implementation of the EU MDR and its guidances, as well as notified bodies struggling with capacity and new processes, are creating a clunky, slow and expensive EU regulatory system that could damage EU industry, delegates heard at the RAPS Convergence meeting earlier this week.
You may also be interested in...
Why The Commission Had No Choice But To Propose New Transition Periods For The EU IVDR
While it was obvious to those in the sector that the implementation of the EU IVD Regulation was heading for a disaster, this article looks at the facts and figures that helped sway the European Commission to propose new transition periods to better manage its implementation.
European Commission Gives In On IVDR Delays: Proposal For New Transition Periods
The pressing circumstances created by the ongoing COVID-19 pandemic has resulted in the commission not only accepting compliance delays for some IVDs, but also longer transitional provisions than expected.
TEAM-NB Training Sessions Aim To Harmonize Best Practice At Time Of Rapid Change
With new EU medtech regulation in place, demand for qualified and well-trained staff at notified bodies is at an all-time high. As an abundance of new auditors are faced with a steep learning curve ahead, moves are afoot to harmonize practices.